Abstract
Converging evidence suggests a possible link between thyroid state and Alzheimers disease (AD), including a higher probability of dementia in individuals with higher TSH levels and a two-fold risk of AD in patients with hypothyroidism. Thyroid hormones modulate factors associated with AD, including amyloid precursor protein expression in the brain, suggesting a possible role for thyroid hormone in AD pathology. The present study is the first to directly evaluate brain thyroid hormone levels in AD. Triiodothyronine (T ) and thyroxine (T ) levels were measured with radioimmunoassay (RIA) in post-mortem samples of prefrontal cortex of patients with pathologically confirmed AD, including Braak stage I-II (n=8), Braak stage V-VI (n=8), and controls without any primary neurological disease (n=8). T levels did not differ between groups. T levels were significantly lower in Braak stage V-VI brains relative to controls, but there was no statistically significant difference between T levels in Braak stage I-II versus controls. Results suggest that the conversion of T to T may be affected in advanced AD, perhaps due to alterations in deiodinase activity. Reduced conversion of T to T3 in AD may be associated with both AD pathology and the clinical presentation of dementia.
Keywords: Thyroid hormones, thyroxine, Alzheimer's disease, dementia
Current Aging Science
Title: Thyroid Hormone Levels in the Prefrontal Cortex of Post-Mortem Brains of Alzheimers Disease Patients
Volume: 1 Issue: 3
Author(s): Jennifer Duncan Davis, Anna Podolanczuk, John E. Donahue, Edward Stopa, James V. Hennessey, Lu-Guong Luo, Yow-Pin Lim and Robert A. Stern
Affiliation:
Keywords: Thyroid hormones, thyroxine, Alzheimer's disease, dementia
Abstract: Converging evidence suggests a possible link between thyroid state and Alzheimers disease (AD), including a higher probability of dementia in individuals with higher TSH levels and a two-fold risk of AD in patients with hypothyroidism. Thyroid hormones modulate factors associated with AD, including amyloid precursor protein expression in the brain, suggesting a possible role for thyroid hormone in AD pathology. The present study is the first to directly evaluate brain thyroid hormone levels in AD. Triiodothyronine (T ) and thyroxine (T ) levels were measured with radioimmunoassay (RIA) in post-mortem samples of prefrontal cortex of patients with pathologically confirmed AD, including Braak stage I-II (n=8), Braak stage V-VI (n=8), and controls without any primary neurological disease (n=8). T levels did not differ between groups. T levels were significantly lower in Braak stage V-VI brains relative to controls, but there was no statistically significant difference between T levels in Braak stage I-II versus controls. Results suggest that the conversion of T to T may be affected in advanced AD, perhaps due to alterations in deiodinase activity. Reduced conversion of T to T3 in AD may be associated with both AD pathology and the clinical presentation of dementia.
Export Options
About this article
Cite this article as:
Davis Duncan Jennifer, Podolanczuk Anna, Donahue E. John, Stopa Edward, Hennessey V. James, Luo Lu-Guong, Lim Yow-Pin and Stern A. Robert, Thyroid Hormone Levels in the Prefrontal Cortex of Post-Mortem Brains of Alzheimers Disease Patients, Current Aging Science 2008; 1 (3) . https://dx.doi.org/10.2174/1874609810801030175
DOI https://dx.doi.org/10.2174/1874609810801030175 |
Print ISSN 1874-6098 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-6128 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Zolpidem Therapy for Movement Disorders
Recent Patents on CNS Drug Discovery (Discontinued) Big Pharma's Recent Challenges
Applied Clinical Research, Clinical Trials and Regulatory Affairs Proprotein Convertase Subtilisin/kexin type 9 Inhibition in Cardiovascular Prevention
Current Pharmaceutical Design Editorial (Thematic Issue: Vascular Dysfunction in Obesity and Insulin Resistance)
Current Vascular Pharmacology Sleep-Related Disorders, Diabetes and Obesity: Understanding the Facts
Current Respiratory Medicine Reviews A Link Between Brain Insulin Resistance and Cognitive Dysfunctions: Targeting Ca2+/cAMP Signalling
Central Nervous System Agents in Medicinal Chemistry Vascular Disease and Insulin-Like Growth Factor-1
Vascular Disease Prevention (Discontinued) Cystathionine Beta Synthase as a Risk Factor for Alzheimer Disease
Current Alzheimer Research Brain Information Sharing During Visual Short-Term Memory Binding Yields a Memory Biomarker for Familial Alzheimer's Disease
Current Alzheimer Research Metal Catalyzed Oxidation of Alpha-Synuclein – A Role for Oligomerization in Pathology?
Current Alzheimer Research Therapeutic Targets in Extracellular Protein Deposition Diseases
Current Medicinal Chemistry Targeting Monoamine Oxidases with Multipotent Ligands: An Emerging Strategy in the Search of New Drugs Against Neurodegenerative Diseases
Current Medicinal Chemistry Emotion and Destination Memory in Alzheimer’s Disease
Current Alzheimer Research Does Parkinson’s Disease and Type-2 Diabetes Mellitus Present Common Pathophysiological Mechanisms and Treatments?
CNS & Neurological Disorders - Drug Targets Neuroinflammation and Alzheimer's Disease: Implications for Microglial Activation
Current Alzheimer Research Thrombosis in Paroxysmal Nocturnal Hemoglobinuria at a Glance: A Clinical Review
Current Vascular Pharmacology Acetylcholinesterase Imaging: Its Use in Therapy Evaluation and Drug Design
Current Pharmaceutical Design Editorial (Hot Topic: Neurodegeneration: The First IBRO-Middle East Neuroscience Conference)
Current Alzheimer Research <i>In Vivo/Ex Vivo</i> EPR Investigation of the Brain Redox Status and Blood-Brain Barrier Integrity in the 5xFAD Mouse Model of Alzheimer's Disease
Current Alzheimer Research Dehydroevodiamine•HCl Protects Against Memory Impairment and Cerebral Amyloid-β Production in Tg2576 Mice by Acting as a β-Secretase Inhibitor
CNS & Neurological Disorders - Drug Targets